Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00753506 · ClinicalTrials.gov registry record · NA
Artemisinin to Reduce The Symptoms of Schizophrenia
A NA study, sponsored by Sheppard Pratt Health System.
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT00753506 is a NA study that has completed, run by Sheppard Pratt Health System. The registered enrollment target is 66 participants.
The verdict
NCT00753506, a NA study, has completed, sponsored by Sheppard Pratt Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the antimalarial compound artemisinin when used in addition to standard antipsychotic medications.
Interventions
- DIETARY_SUPPLEMENT Artemisinin
- DIETARY_SUPPLEMENT Identical looking placebo capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00753506
The ClinicalTrials.gov registry entry for NCT00753506 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sheppard Pratt Health System, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Artemisinin is the first listed.
NCT00753506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00753506 about?
NCT00753506 is a clinical study titled "Artemisinin to Reduce The Symptoms of Schizophrenia". The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the antimalarial compound artemisinin when used in addition to standard antipsychotic medications.
What is the current status of trial NCT00753506?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2008-08. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00753506?
The interventions under investigation include: Artemisinin (DIETARY_SUPPLEMENT), Identical looking placebo capsule (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00753506?
This trial is sponsored by Sheppard Pratt Health System, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.